Rafa Laboratories   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Jerusalem Israel (1958)
Status: No NME R&D (1958)

Organization Overview

First Clinical Trial
2001
NCT00128739
First Marketed Drug
2018
atropine
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Rafa Laboratories | RAFA LABS LTD

Active Ingredients

Marketed Drugs (2)

atropine (2018)

midazolam (versed) (2022)

Drugs in Phase 4 Trials (2)

fluoxetine (prozac) (1 trial)

hypericum perforatum (1 trial)

Drugs in Phase 3 Trials (1)

budesonide (rhinocort) (1 trial)

Drugs in Phase 2 Trials (1)

tetrahydrocannabinol (1 trial)

Drugs in Phase 1 Trials (1)

midazolam (versed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 4)

Depressive Disorder (Phase 4)

Graft vs Host Disease (Phase 3)

Nausea (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5